UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2242-5
Program Prior Authorization/Medical Necessity
Medication Intrarosa® (prasterone)
P&T Approval Date 6/2021, 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Imvexxy® (estradiol) vaginal insert, Intrarosa (prasterone) vaginal insert, Osphena®
(ospemifene) oral tablet, and Premarin® (conjugated estrogens) vaginal cream are
indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and
vaginal atrophy (VVA), due to menopause. Osphena is also indicated for the treatment of
moderate to severe vaginal dryness, a symptom of VVA, due to menopause and Premarin
vaginal cream is indicated for the treatment of atrophic vaginitis and kraurosis vulvae.
2. Coverage Criteriaa:
A. Initial Authorization
1. Intrarosa will be approved based on all of the following criteria*:
a. Diagnosis of moderate to severe dyspareunia
- AND-
b. Patient has vulvar and vaginal atrophy due to menopause
-AND-
c. History of failure, contraindication, or intolerance to two of the following:
1) Imvexxy (estradiol)
2) Osphena (ospemifene)
3) Premarin vaginal cream
Authorization will be issued for 12 months
B. Reauthorization
1. Intrarosa will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
© 2025 UnitedHealthcare Services Inc.
1
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
* Coverage of medications for the treatment dyspareunia is based on benefit design. Please refer to
member’s specific benefits for coverage determination.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Imvexxy [package insert]. Boca Raton, FL: TherapeuticsMD, Inc.; November 2023.
2. Intrarosa [package insert]. East Hanover, NJ: Millicent U.S. Inc.; November 2020.
3. Osphena [package insert]. Princeton, NJ: Duchesnay USA, Inc.; February 2025.
4. Premarin cream [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals LLC;
February 2024.
5. The 2020 genitourinary syndrome of menopause position statement of The North
American Menopause Society. Menopause: The Journal of The North American
Menopause Society. 2020: 27(9); 976-92.
Program Prior Authorization/Medical Necessity – Intrarosa
Change Control
Date Change
6/2021 New program
6/2022 Annual review. Updated references.
6/2023 Annual review. Updated references & realigned numbering.
6/2024 Annual review. Updated references.
6/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services Inc.
2